Loading stock data...
Mind Medicine (MindMed) Inc. (MNMD) Company Information
Complete company information for MNMD including business overview, key executives, headquarters location, corporate structure, and company details. Learn about MNMDleadership team and business operations.
Company Profile
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Website: https://www.mindmed.co
Headquarters: One World Trade Center, New York, NY 10007, United States
Phone: 212 220 6633
Full Time Employees: 74
Key Executives:
CEO & Director: Mr. Robert BarrowTotal Pay: $997,010
Chief Legal Officer & Corporate Secretary: Mr. Mark R. Sullivan J.D.Total Pay: $638,607
Chief Medical Officer: Dr. Daniel Rollings Karlin M.A., M.D.Total Pay: $703,319
Co-Founder & Clinical Advisor: Dr. Scott M. Freeman M.D.Total Pay: $311,057
Co-Founder: Mr. Leonard Latchman
Chief Financial Officer: Ms. Brandi L. Roberts CPA, M.B.A.
Governance Risk Metrics:
Overall Risk: 4/10
Audit Risk: 7/10
Board Risk: 3/10
Compensation Risk: 7/10
Additional Information:
Market Cap: $741.86M
Enterprise Value: $589.40M
Shares Outstanding: 76.09M
Float Shares: 70.25M
Last Fiscal Year End: 12/31/2024
Next Fiscal Year End: 12/31/2025
Most Recent Quarter: 6/30/2025
Last Stock Split: 8/29/2022(1:15)